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Summary The EGF receptor is a transmembrane glycoprotein exerting mitogenic effects on epithelial cells.
The purpose of the present study was to develop a sensitive enzyme-linked immunosorbent assay (ELISA) for
determination of the epidermal growth factor receptor (EGFR) protein to examine whether the receptor was
overexpressed in head and neck squamous cell carcinomas compared with the normal counterpart, and to
establish whether clinicopathological correlations were present by investigating a broad spectrum of
parameters (tumour size, clinical stage, positive lymph nodes, tumour site, histological grade, keratinisation,
preoperative irradiation and clinical outcome). The assay employs two commercially available monoclonal
antibodies, both detecting protein epitopes. The material comprises 60 head and neck carcinomas, correspon-
ding normal tissue and normal oral mucosa from healthy individuals. The study demonstrates significantly
higher receptor levels in tumours compared with normal tissue (P<0.002) and a range in tumours and normal
tissues of 0.4-10.5 and 0.1-4.3 nmol g-' membrane protein respectively. Quantitation of receptors in normal
mucosa emphasises the importance of using the patients' corresponding normal tissue, because using the
patients' mucosa resulted in 83% overexpression, while using normal mucosa from healthy individuals only
demonstrated overexpression in 50% of cases. No significant clinicopathological correlations could be estab-
lished, although the mean values for EGFR increased with tumour size and advanced clinical stage. Further-
more, the prognostic value concerning disease-free survival, recurrence and the time interval for recurrence
were investigated but no significance could be demonstrated. In conclusion, the investigation supports the
theory of overexpression of EGFR protein as a common motif for malignant epithelial tumours, but
limitations in interpretations are demonstrated and discussed further.
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Epidermal growth factor receptor (EGFR) is a transmemb-
rane cell-surface glycoprotein, molecular weight 170 kDa,
that binds peptides from the epidermal growth factor (EGF)
family. This is a rapidly growing family consisting of a
number of structurally and/or functionally related mem-
brane-anchored molecules (Massague and Pandiella, 1993).
Transforming growth factor alpha (TGF-x), amphiregulin
(AR), vaccinia virus growth factor (VVGF), heparin-binding
EGF-like growth factor (HB-EGF) and betacellulin bind to
the EGFR which is present on cells derived from all three
germ layers, including the proliferative compartment of
epithelia (De Larco and Todaro, 1978; Gusterson et al.,
1984; Nanney et al., 1984; Stroobant et al., 1985; Shoyab et
al., 1989; Higashiyama et al., 1991; Sasada et al., 1993). The
biological activities are initiated through a tyrosine kinase
which is localised to the intracellular domain of EGFR
(Chen et al., 1987). Tyrosine kinase activity of the receptor is
activated in clathrin-coated pits by ligand-induced dimerisa-
tion. Activated tyrosine kinase initiates a cascade of intracel-
lular events, such as autophosphorylation of tyrosine resi-
dues, a rise in cytosolic calcium ions and pH and increased
transcription of responsive genes such as c-fos, c-myc and
c-ras, leading to pleotropic effects on cells including the
stimulation of migration and mitogenesis (Barrandon and
Green, 1987; Chen et al., 1987).
EGFR is considered as a proto-oncogene product sharing
sequence homology with oncogene and proto-oncogene pro-
ducts from v-erbB-1, c-erbB-2 (neu/HER-2), c-erbB-3 (HER-
3) and c-erbB-4 (HER-4) (Downward et al., 1984; Schechter
et al., 1985; Kraus et al., 1989; Plowman et al., 1993). The
highest degree of sequence identity is in the tyrosine kinase
domain, which is essential for the biological effects of the
EGFR (Chen et al., 1987).
The importance of the EGFR system in proliferation is
demonstrated using antibodies to EGFR achieving reversible
Go growth arrest in normal epithelial cells (Stampfer et al.,
1993). Concerning tumour biology elevated expression of
EGFRs has been found to be necessary for malignant trans-
formation ofNIH-3T3 cells in culture (Riedel et al., 1988; Di
Marco et al., 1989). In addition, in vivo experiments have
shown that overexpression of EGFR is common in epider-
moid malignancies and can be detected in human tumours
(Ozanne et al., 1986; Nicholson et al., 1988; Yasui et al.,
1988; Ozawa et al., 1989; Grimaux et al., 1990; van Dam et
al., 1991). Last but not least, amplification of the EGFR
gene and/or overexpression of the gene product is correlated
with a poor prognosis in breast cancer, oesophageal cancer
and malignant gliomas (Nicholson et al., 1988; Ozawa et al.,
1989; Grimaux et al., 1990; Hurtt et al., 1992). These obser-
vations together suggest that elevated EGFR levels may play
a role in either initiation or progression of malignancy.
In a recent study, using immunohistochemistry, we demon-
strated the presence of EGFRs in 55 head and neck carcino-
mas (Christensen et al., 1992a,b). A number of quantitative
studies have demonstrated overexpression of EGFR in head
and neck carcinomas (Ishitoya et al., 1989; Kawamoto et al.,
1991; Santini et al., 1991; Scambia et al., 1991). Some of
these studies demonstrated a correlation with tumour size
and clinical stage (Kawamoto et al., 1991; Santini et al.,
1991), others did not (Ishitoya et al., 1989; Scambia et al.,
1991).
The aim of the present study was to develop a sensitive
two-site ELISA for quantitation of receptor proteins in head
and neck carcinomas and to elucidate whether further clin-
icopathological correlations could be established with for
example, histological grade, the effect of preoperative irradia-
tion, nodal status, tumour location; and whether the overex-
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pression of the receptor protein could be an independent
prognostic indicator for recurrence and/or patient survival.
Materials and methods
Patients
Fresh tissue samples were collected from 60 consecutive
patients (Table I) who underwent operations during 1990-93
in the Department of Oto-Laryngology - Head and Neck
surgery, Rigshospitalet, University Hospital, Copenhagen.
Most of the tumours were located in the oral cavity. Other
locations included the nose and maxillary sinus. In 41 cases
corresponding normal tissue was included. In addition, ten
normal specimens of oral mucosa were obtained from healthy
non-smokers (mean age 29 years; range 25-37 years) and ten
from age-matched patients operated for non-cancer diseases
(e.g. nose fracture or otitis media; mean age 62 years; range
48-78 years). The project was approved by the regional
Committee of Scientific Ethics, Copenhagen, and informed
consent was obtained. Thirty-eight of the patients had
received preoperative irradiation (62-68 Gy) (Table I). No
patients had been treated with chemotherapeutic agents. All
the patients were staged according to the UICC TNM
classification (Spiessl et al., 1990). At follow-up 30 patients
suffered from recurrence.
The samples were obtained within 10-30min of surgery
and frozen at -80°C. In order to ensure that the receptor
protein was stable during this period, seven tumour speci-
mens and corresponding normal tissues were divided into
three pieces and frozen after 10, 20 and 30 min at room
temperature.
In all cases verification of the tumour was made on frozen
sections cut from the biopsies and stained with haematoxy-
lin-eosin. Fifty-four of the tumours were squamous cell
carcinomas, most of which were moderately differentiated
(Table I). In addition, the material included six malignant
salivary gland tumours, three adenocarcinomas, two muco-
epidermoid carcinomas and one clear cell carcinoma. The
histological grade of the squamous cell carcinomas was deter-
mined on paraffin sections according to standard criteria
(Kissane, 1990).
Table I Clinicopathological parameters in 60
and neck carcinomas
patients with head
Patient characteristics
No. of 60
patients
Mean age (range) 59 (36-87)
Sex
Male 45
Female 15
Site
Stage
Oral cavity
Larynx
Other location
I 11
II 12
III 17
IV 20
Histopathology
Well-differentiated squamous cell carcinomas 9
Moderately differentiated squamous cell 37
carcinomas
Poorly differentiated squamous cell 8
carcinomas
Salivary gland carcinomas 6
Subsequent treatment
Preoperative irradiation 38
Primary surgery 22
Extraction ofEGFR
In the normal tissue, the lamina propria was separated from
the surface epthelium. The biopsies weighing between 20 and
1300 mg were cut into 2-3 mm-3 fragments and homogenis-
ed at 0°C by an ultra-turrax system (Janke and Kunkel,
Staufen, Germany) in ten volumes (w/v of solution contain-
ing 10 mM piperazine-N,N'-bis(2-ethanesulphonic acid)
(Pipes), 3 mM magnesium chloride, 1 mM EGTA, 1 mM
phenylmethylsulphonyl fluoride (PMSF) and 400 mM sodium
chloride, pH 7.4. This solution prevents the association of
EGFRs to actin filaments (van Bergen en Henegouwen et al.,
1992). This procedure was followed by ultrasonic homo-
genisation 5 x 10 s and terminated by centrifugation for
40 min at 20 000 g (Sigma 3K20, Harz, Germany). The mem-
brane pellet was resuspended in ten volumes (w/v) of the
above-mentioned buffer and treated with ultrasonic
homogenisation for 5 x 10 s. Receptor extraction was per-
formed by incubating the homogenates with ten volumes
(w/v) 2% triton X-100 (Merck, Damstadt, Germany) at 0°C
overnight, followed by centrifugation for 40 min at 20 000g.
The supernatant was frozen rapidly at - 80°C until EGFR
and protein determination was carried out. Most EGFR was
present in the extracted membrane preparation, as judged
from analysis of the first supernatant and analysis of the
pellet which was re-extracted twice. As determined from
analysis of extracts from one tumour and one placenta sam-
ple, 4-6% of the receptor was present in the first super-
natant and none was present in the supernatant after the
second extraction.
ELISA
Three monoclonal mouse antibodies detecting a protein
epitope (Amersham, Denmark; code no. RPN 513, Onco-
gene, USA; cat. nos. GROl and GR15) (Waterfield et al.,
1982; Sato et al., 1983; Gill et al., 1984) were tested for the
ability to form a pair and two rabbit polyclonal antibodies
(P91089, P91090) were tested as capture antibodies with
GROl, GR15 and RPN 513 as detector antibodies respec-
tively, employing a previously described method (Engbaek
1994). The optimal combination was to employ RPN 513
(IgG2b) as capture antibody and GROl (IgGI) as detector
antibody. To optimise the binding of capture antibody, rab-
bit anti-mouse IgG2b was coated to the wells (Dakopatts,
Denmark; code Z015) (Mangili et al., 1987). Titrations of the
anti-mouse, capture and detector antibodies were performed
as described by Engbaek (1994). EGFR from placenta mem-
branes extracted as described for tissue samples was used as
calibrator. The membranes were isolated from fresh-frozen
term human placenta (Hock et al., 1980), and the number of
receptors present was analysed by Scatchard analyses of
binding data for binding of ['25I]EGF to the particular recep-
tor (Nex0 and Hansen, 1985).
Receptor extracts from placenta tissue and tumour speci-
mens showed linear dilution curves in a range of 0.02-
0.65 nmol EGFR g-' membrane protein. The assay had a
detection limit of 0.08 nmol 1-. Recovery of placenta lysates
used as high control in the EEISA added to phosphate buffer
with 0.1% polysorbate 20 (Tween), fetal liver, placenta and
tumour lysates was between 0.99-1.16 (n = 4). The interassay
precision was 14% (mean 0.17 nmol 1') and 7% (mean
0.50 nmol [') as judged from analysis of controls prepared
from placenta extracts each determined 36 times over a
period of 4 months. The values obtained for EGFR was
independent of the amount of tissue employed (20, 50, 100
and 1000 mg) as judged from analyses of normal human fetal
liver and kidney tissues [liver 0.58-0.64nmolg' membrane
protein (n = 4); kidney 0.63-0.76 nmol g-' membrane pro-
tein (n = 4)].
For routine use th, 96-well ELISA plates (Nunc, Life
Technologies, Denmark) were coated with 100 I per well
rabbit anti-mouse immunoglobulin IgG2b 2.0 ng al-' in
50 mM sodium carbonate buffer pH 9.6 at 4°C and incubated
overnight. The capture antibody was diluted to 0.25ng,u1'
in a buffer containing 10 mM sodium phosphate and 400 mM
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sodium chloride pH 7.4 supplemented with 0.1% polysorbate
20 (Tween) (Merck-Schuchardt, Munich, Germany) and
100 pl per well was absorbed on the ELISA plate by
incubating at 4°C overnight and washed three times with
200 dL washing buffer (10 mm sodium phosphate, 145 mM
sodium chloride, 0.1% polysorbate 20 and pH 7.4). The sam-
ples and calibration standards were diluted 1:2 and 1:5 in
washing buffer supplemented with normal mouse serum
(0.24nglil-') (Dakopatts; code no. X910). Aliquots of 501al
of samples and calibration standards were applied to each
well, incubated for 3 h and washed three times with washing
buffer (200 yl). The detector antibody was biotinylated
(Bayer and Wilcheck, 1980) and diluted to 0.075 ng l1 in
the same buffer as the capture antibody and supplemented
with normal mouse serum (0.24 ng il -l. Each well was
incubated overnight with 100 p1 of the detector antibodies at
4'C and washed with washing buffer three times (200 tLI). The
detecting antibody bound to EGFR was visualised by
incubation for 30 min with 100 pLI horseradish-peroxidase-
conjugated avidin diluted 1:100 in washing buffer
(Dakopatts; code no. P364) followed by 20 min incubation
with the enzyme substrate 3,3',5,5'-tetramethylbenzidine
(TMB) (Kirkegaard and Perry laboratories, MA, USA; cat.
no. 50-76-00). The reaction was terminated by adding 100 p1
1 M phosphoric acid resulting in a yellow colour. The
immunoreactions were quantified by reading the absorbances
at 450 nm and 620 nm (Multiskan MMC/340, labsystems,
Finland), using a cubic spline curve-fitting procedure for
calculating the results (Reinsch, 1967).
Other methods
The concentration of protein was determined with a BCA
method (Pierce, IL, USA; code no. 23225).
Radiolabelled ligand assay
The EGF binding of the solubilised receptor was analysed as
described by Nex0 et al. (1979) by adsorbing the solubilised
receptor to Con A-Sepharose before incubation with 1251_
labelled EGF. Human radiolabelled EGF was prepared by
the chloramin T method (J0orgensen et al., 1988).
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Figure 1 Quantitation of EGFRs in head and neck carcinomas.
Comparison between a ['251]-EGF binding assay and EGFR
immunoreactivity measured in the ELISA system. The solubilised
EGFRs regained their ligand recognition after immobilisation on
Con A-Sepharose. The bead-bound receptors were then incubated
with ['251]-EGF and the radioactivity measured. The radioactivity
bound to the receptor was correlated with the value measured in
the ELISA, correlation coefficient = 0.90.
Statistical analysis
One tumour specimen with a very high number of EGFRs
(76 nmol g-' membrane protein) was excluded from the
statistical calculations. Parametric statistic methods were
chosen, as data did not show any systematic deviation from
normality. Correlation analyses (Pearson correlation coeffi-
cients) were performed for all pairs of variables, both the
clinicopathological data and paired values for EGFR. Paired
EGFR values from tumour and normal tissue were cor-
related, since the differences were independent of the values
obtained from the normal mucosa and approximately nor-
mally distributed. Therefore EGFR values from tumour and
normal tissue respectively and the differences between the
paired observations of tumour and normal tissue from
patients, were investigated by analyses of variances classified
by one or two of the clinicopathological factors in order to
investigate any main effects or interactions of these factors.
EGFR values in normal tissues from patients and healthy
persons were compared by one-way analysis of variance. The
time of disease-free survival and the time until recurrence
were calculated for 50 of the 53 patients with squamous cell
carcinomas, while data from three patients were not
available. Differences in the number of EGFRs and
clinicopathological parameters at the time of operation
between the group of patients with recurrence and the group
without recurrence was investigated by one-way analysis of
variance or chi-square test. The level of significance was
P<0.05.
Results
The ELISA developed for quantitation of EGFR immunore-
activity correlates with the results obtained with an assay
that quantitates EGF binding ability of EGFR with a cor-
relation coefficient of 0.90 (Figure 1). The advantage of the
ELISA method is that only 20 mg of tissue is required for an
analysis that quantitates EGFRs from 0.08 nmol 1i (approx-
imately 0.034 nmolg-' membrane protein) with a precision
of around 10%.
A principal condition for using the assay was that the
receptor protein was stable in 30 min. Statistical analysis did
not demonstrate any significant differences in receptor
measurement at 10, 20 or 30 min for tumour specimens
(P>0.75) or normal tissues (P>0.25).
Patients with squamous cell carcinomas
In general, tumour specimens revealed overexpression of
EGFR (0.4-10.5 nmolg-' membrane protein) compared
with the normal counterpart (0.1 -4.3 nmol g-' membrane
protein) (Figures 2 and 3). Only seven of the biopsies demon-
strated, fewer EGFRs in the tumour specimens than the
normal epithelia (Figure 2). The difference between tumour
and normal tissue was significant with P<0.002 (paired t-
test). No significant correlation was observed between the
expression of EGFRs (expressed as absolute values or differ-
ences between tumour and normal tissue) and tumour size or
clinical stage, although the mean differences were higher in
samples from patients grouped as T2, T3, T4 and SII, SIII,
SIV as compared with the values in samples obtained from
patients grouped as TI and SI with P = 0.084 and 0.25
respectively. The clinicopathological data (i.e. histological
grade, keratinisation of the squamous cell carcinomas,
positive lymph nodes, anatomical locations of the tumours
and the effect of preoperative irradiation), were analysed and
no significant correlation with EGFR expression was found
in tumour specimens (n = 53), or in normal tissue (n = 41), or
with the difference between tumour and normal tissue (n =
41). The group of patients receiving preoperative irradiation
(n = 38) was analysed separately concerning residual (n = 11)
or recurring tumour (n = 28), however, no significant differ-
ence in EGFR level was seen.
Receptor expression in the tissue samples and the patients'
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clinical outcome were evaluated. No significant correlation
was found to EGFR expression at time of operation between
patients with recurrence (n = 30) and patients with disease-
free survival (n = 20) (P> 0.35). The mean observation time
was 319 days (range 12-1050 days). In the group of patients
with recurrence, time until recurrence did not depend on
EGFR level in tumour tissue at operation time (P>0.45).
Mean observation time and range in this group was 195 days
(range 12-489 days) respectively. The same calculation was
made for the difference between tumour tissue and normal
tissue and no significance was found between recurrence
(n = 26) or disease-free survival (n = 13) (P> 0.30).
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Patients with malignant salivary gland carcinomas
EGFRs measured in malignant salivary gland tumours dem-
onstrated values similar to squamous cell carcinomas
(P>0.1) (Figure 3) (mean 2.3; range 0.7-4.1 nmol g-' mem-
brane protein). These tumours were derived from the minor
salivary glands and, as corresponding normal tissue was not
obtainable, overexpression could not be investigated.
Normal mucosafrom patients and healthy individuals
Analysis of receptor expression in normal tissue (n = 41)
from patients with squamous cell carcinoma did not demon-
strate a significantly higher level compared with healthy indi-
vidual patients with non-cancer diseases (n = 20) (Figure 3).
However, in the subgroup consisting of younger healthy
individuals (mean age 29 years), EGFR expression was
significantly higher (mean 2.5; range 1.2 -3.4 nmol g-' mem-
brane protein) compared with the patients' corresponding
normal tissue (mean 1.7; range 0.1 -4.3 nmol g-' membrane
protein) (P<0.03). In an age-matched group of individuals
with non-cancer diseases (n = 10) the mean EGFR level was
higher (mean 2.1; range 1.7-3.1 nmol g-' membrane protein)
compared with the mean value obtained from the patients'
normal mucosa (mean 1.7; range 0.1 -4.3 nmol g-' memb-
rane protein), but not significantly.
Patients' normal counterparts were also included in the
analysis in order to evaluate if the EGFR level in surround-
ing non-diseased tissue reflected correlations with tumour size
and/or clinical stage. However, no correlation could be deter-
mined. No significant difference in EGFR level was seen in
normal epithelia between patients treated with primary
surgery (n = 13) and patients receiving preoperative irradia-
tion (n = 28) (P> 0.25).
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Figure 2 EGFR immunoreactivity in
cell carcinomas (n = 41) as compared
normal tissue from the same patient.
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Figure 3 The content of EGFR immunoreactivity in squamous
cell carcinomas (mean 3.6; range 0.4- 10.5 nmol g-' membrane
protein), corresponding normal mucosa (mean 1.7; range 0.1 -4.3
nmol g-' membrane protein), normal oral mucosa from patients
with non-cancer diseases and normal mucosa from healthy indi-
viduals (mean 2.3; range 1.2-3.4 nmol g-' membrane protein)
and salivary gland carcinomas (mean 2.3; range 0.7-4.1 nmol g-'
membrane protein).
Discussion
It is well understood that growth regulation of normal cells is
controlled in part by the interaction of growth factors pro-
duced by the cells or neighbouring cells and growth factor
receptors present on the cells. Abnormal expression of
growth factors and their receptors or abnormal responses to
growth factors or both may be involved in cellular transfor-
mation and in the maintenance of the transformed phenotype
(Cross and Dexter, 1991). EGFR is an important mitogenic
molecule regarding epithelial cells, and overexpression seems
to be a general motif for many malignant epithelial tumours.
Therefore a number of studies quantitating the receptor in
tumour specimens have been carried out in an attempt to
define a molecule correlating with clinical parameters and/or
clinical outcome, and such assays have indicated a clinical
usefulness of quantitation of EGFRs in tumours such as
gliomas, breast cancer and bladder cancer (Grimaux et al.,
1990; Neal et al., 1990; Hurtt et al., 1992). So far, little
attention has been paid to the methodological aspects of
receptor quantitation and results from different studies are
difficult to compare. Most of the reported clinical studies
have used radiolabelled ligand assays employing 251I-labelled
EGF. Methodological variations such as processing of the
tumour tissue to yield membrane preparation and multipoint
or two-point binding assay could explain some discrepancies
in the results, notably as regards the distribution of the levels
(mean, median) and the indicated thresholds for 'positivity'.
However, even if a standardised methodology could be emp-
loyed the '251I-labelled EGF binding assay requires a relatively
large amount of tissue (0.5 1 g) and is in general less precise
than immunoassays.
We have developed an ELISA method which allows EGFR
quantitation to be carried out on small tissue samples
(20 mg). Our ELISA demonstrates overexpression of EGFR
in 83% of head and neck tumour specimens. The mean
values in our assay are high (mean 3.6; range 0.4-10.5
nmol g- ' membrane protein) compared with two other
studies using a similar assay for quantitation of EGFRs in
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breast carcinomas (mean 0.02; range 0.001-0.1 nmol g-' meters, although the mean values for EGFR increased with
membrane protein and mean 0.006; range 0-0.2 nmol g-' tumour size and advanced clinical stage.
membrane protein respectively) (Grimaux et al., 1990; In 1953 Slaughter et al published a classic report describ-
Spyratos et al., 1994). One reason for the differences could be ing the novel concept they called 'field cancerisation'. This
the method used for receptor extraction. We have used a term referred to the basic pathogenic process that links the
method that prevents the association of EGFR with the actin originally diagnosed tumours from head and neck cancer
filaments and a relatively long incubation time (12 h) with patients with other primary tumours in the oropharynx,
2% triton X-100 (Hollenberg, 1990; van Bergen en Henegou- larynx, oesophagus and lung. Our study comparing receptor
wen et al., 1992). Another reason may be the use of different quantities in normal mucosa from patients suffering from
calibration standards. So far no definitive/international/ head and neck cancer with mucosa from healthy non-
WHO defined calibration standard is available. Finally it is smokers and patients with non-cancer diseases was per-
of course possible that squamous cell carcinomas in general formed in an attempt to investigate whether EGFR could
express more EGFRs than adenocarcinomas. serve as a marker for 'field cancerisation' or 'condemned
Besides these methodological and standardisation problems mucosa syndrome' (Slaughter et al., 1953). The results, how-
other aspects may be of importance. One of these is the ever, did not demonstrate significantly more EGFRs in
stromal component, which is variable and which contributes patients compared with the age-matched control group.
to membrane protein and may be responsible for the wide Another study including oral mucosa from patients with
range of receptor expression. This may explain why we found head and neck carcinomas and from control patients without
seven cases that expressed more EFGRs in the corresponding cancer has demonstrated, using Northern blot increased
normal tissue than in the tumour (Figure 2) and may also EGFR mRNA in the group of patients suffering from cancer
serve as an explanation for the tumour specimen expressing (Grandis and Tweardy, 1992). These results may indicate that
an extremely high level of EGFR (76 nmol g' membrane the receptor protein should be overexpressed as well. How-
protein). Another factor in performing these studies is that ever, another study comparing EGF at mRNA and protein
the receptor may be expressed at different levels within the level in colon cancer cell lines did not demonstrate linearity
same tumour; in other words tumour heterogeneity at EGFR between the transcription and translation product, indicating
level. To overcome this problem the entire tumour has to be that not all mRNA may be translated to protein (Huang et
investigated, which is not possible in most cases. al., 1992). In summary this part of our study rejects the
Other studies have demonstrated overexpression in head hypothesis of EGFR protein as a marker for 'field cancerisa-
and neck carcinomas (Ishitoya et al., 1989; Kawamoto et al., tion' in normal mucosa and suggests that the overexpression
1991; Santini et al., 1991; Scambia et al., 1991) (Table II). first develops in later stages of carcinogenesis. Concerning
The methods used in these studies are Western blotting, oral dysplasia quantitative studies have yet to be performed,
radiolabelled ligand assay and dot blot (Table II). One but immunohistochemical results have demonstrated expres-
important reason for the varying results may be the sion of EGFR in all layers of the epithelium, results which
definition of normal tissue. Some of the studies used oral or may also indicate overexpression (Christensen et al.,
laryngeal mucosa from healthy individuals (Scambia et al., 1992a).
1990; Kawamoto et al., 1991). Another study used mucosa The mechanism leading to increased expression of EGFR
from both healthy individuals and placenta (Ishito et al., in head and neck carcinomas is not usually gene
1989). The only study that used normal tissue from patients amplification, which is seen in only 5-20% of patients
was that of Santini et al. (1991) and, in agreement with our overexpressing the receptor and is not related to clinical
study, they demonstrated overexpression in most tumours outcome (Eisbruch et al., 1987; Ishitoya et al., 1989; Kearsley
(Table II). et al., 1991; Leonard et al., 1991; Furuta et al., 1992; Irish
We have looked at prognostic value, tumour size and and Bernstein, 1993). The major mechanism for overexpres-
clinical stage as well as a number of other relevant para- sion thus develops post-transcriptionally and/or alternatively
meters in an attempt to establish further clinicopathological post-translationally. In a study including 17 specimens from
correlations. However, within our sample set, no correlation head and neck carcinomas no amplification of mRNA was
was evident between overexpression and the examined para- found, thus the mechanisms leading to overexpression are
Table II Studies quantitating EGF receptors in head and neck squamous cell
carcinomas
Percentage of
Normal Tumour tumours with
Reference Method tissue tissue overexpression
Ishitoya et al. (1989) Western Healthy n = 21 53
blot individuals
(n = 2) and
placenta
Scambia et al. (1991) Radiolabelled Healthy n = 41 50
ligand assay individuals
(n = 20)
Kawamoto et al. (1991) Dot blot Healthy n = 41 50
individuals
(n = 8)
Santini et al. (1991) Radiolabelled Corresponding n = 70 98
ligand assay normal tissue
from patients
(n = 60)
Present study ELISA Corresponding n = 41 83
normal tissue
from patients
(n = 41)
Healthy n = 54 50
age-matched
individuals
(n= 10)
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more likely mRNA stability and/or enhanced protease insen-
sitivity (Eisbruch et al., 1987). In accord with this hypothesis
EGFR in A431, a cell line established from a vulva
squamous cell carcinoma, appears to be degraded more
slowly than in human fibroblasts (Wrann and Fox 1979,
Krupp et al., 1982), indicating enhanced protease insensitivity
in malignant cells compared with normal cells.
Head and neck carcinomas have been investigated for
other oncogene and proto-oncogene products besides EGFR
(Merritt et al., 1990; Kearsley et al., 1991; Leonard et al.,
1991). The c-erbB-2 proto-oncogene product, which shares
sequence homology with EGFR and which in breast cancer
has been related to clinical outcome, has been found to be
expressed in a very few to 50% of specimens from head and
neck carcinomas and not related to clinical outcome (Schech-
ter et al., 1985; Kearsley et al., 1991; Field et al., 1992). One
reason may be that this proto-oncogene product is expressed
in particular in secretory cells and is therefore linked with
adenocarcinomas (Gullick 1991).
The importance of EGFR determination for head and
neck cancer remains a contentious issue and currently it is
not possible to evaluate this fully, but overexpression of this
mitogenic receptor seems to be a general motif for these
types of tumour and may contribute to the unregulated or
abberrant proliferation observed in the malignant phenotype.
It has not been possible to establish significant clinico-
pathological correlations at EGFR level. One reason may be
methodological aspects as mentioned above, another that the
EGFR system consists of both the receptor and a group of
different ligands, which also have to be elucidated, before a
final statement concerning the clinical relevance of this
system can be confirmed.
Acknowledgements
The authors are indebted to Mrs Inger-Marie Jensen for skilful
technical assistance. The authors are also indebted to the Statistical
Research Unit, University of Copenhagen for providing statistical
assistance. The study was supported by the Danish Research Coun-
cil, the Boel Foundation and the Danish Cancer Research Associa-
tion.
References
BARRANDON Y AND GREEN H. (1987). Cell migration is essential
for sustained growth of keratinocyte colonies: the roles of trans-
forming growth factor-a and epidermal growth factor. Cell, 50,
1131- 1137.
BAYER EA AND WILCHECK M. (1980). The use of avidin-biotin
complex as a tool in molecular biology. Methods Biochem. Anal.,
26, 1-45.
CHEN WS, LASAR CS, POENIE M, TSIEN RY, GILL GN AND ROSEN-
FELD MG. (1987). Requirement for intrinsic protein tyrosine
kinase in the immediate and late actions of the EGF receptor.
Nature, 328, 820-823.
CROSS M AND DEXTER TM. (1991). Growth factors in development,
transformation, and tumorigenesis. Cell, 64, 271 -280.
CHRISTENSEN ME, THERKILDSEN MH, HANSEN BL., ALBECK H,
HANSEN GN AND BRETLAU P. (1992a). Epidermal growth factor
receptor expression on oral mucosa dysplastic epithelia and
squamous cell carcinomas. Eur. Arch. Otorhinolaryngol., 249,
243 247.
CHRISTENSEN ME, THERKILDSEN MH, HANSEN BL, HANSEN GN
AND BRETLAU P. (1992b). Immunohistochemical detection of
epidermal growth factor receptor in laryngeal squamous cell car-
cinomas. Acta OtolarYngol.. 112, 734- 738.
DE LARCO JE AND TODARO GJ. (1978). Growth factors from
murine sarcoma virus-transformed cells. Proc. Natl Acad. Sci.
U.S.A., 75, 4001-4005.
Di MARCO E, PIERCE JH, FLEMING TP. KRAUS MH, MOLLOY CJ.
AARONSON SA AND DI FIORE PP. (1989). Autocrine interaction
between TGFa and the EGF-receptor: quantitative requirements
for induction of the malignant phenotype. Oncogene, 4, 831 -838.
DOWNWARD J, YARDEN Y, MAYES E. SCRACE G, TOTTY N,
STOCKWELL P, ULLRICH A, SCHLESSINGER J AND WATER-
FIELD MD. (1984). Close similarity of epidermal growth factor
receptor and v-erb-B oncogene protein sequences. Nature, 307,
521 -527.
EISBRUCH A, BLICK M. LEE JS, SACKS PG AND GUTTERMAN J.
(1987). Analysis of the epidermal growth factor receptor gene in
fresh human head and neck tumors. Cancer Res., 47, 3603-3605.
ENGBAEK F. (1994). A general procedure for optimizing concentra-
tions of capture antibody, biotinylated detecting antibody, and
enzyme-labeled avidin in ELISAs: Application to assays for a-
fetoprotein, prolactin, FSH and LH in serum. J. Clin. Immuno-
assay, 17, 151- 155.
FIELD JK, SPANDIDOS DA, YIAGNISIS M, GROSNEY JR, PAPADIMI-
TRIOU K AND STELL PM. (1992). C-erbB-2 expression in squa-
mous cell carcinoma of the head and neck. Anticancer Res., 12,
613-620.
FURUTA Y, TAKASU T, ASAI T, YOSHIMURA S, TOKUCHI F,
SHINOHARA T, NAGASHIMA K AND INUYAMA Y. (1992). Clini-
cal significance of the epidermal growth factor receptor gene in
squamous cell carcinomas of the nasal cavities and paranasal
sinuses. Cancer, 69, 358-362.
GILL GN, KAWAMOTO T. COCHET C, LE A, SATO JD, MASUI H,
MCLEOD C AND MENDELSOHN J. (1984). Monoclonal anti-
epidermal growth factor receptor antibodies which are inhibitors
of epidermal growth factor binding and antagonists of epidermal
growth factor-stimulated tyrosine protein kinase activity. J. Biol.
Chem., 259, 7755-7760.
GRANDIS JR AND TWEARDY DJ. (1992). The role of peptide growth
factors in head and neck carcinoma. Otolaryngol. Clin. N. Am.,
25, 1105-1115.
GRIMAUX M, MADY E, REMVIKOS Y, LAINE-BIDRON C AND
MAGDELE NAT H. (1990). A simplified immuno-enzymetric assay
of the epidermal growth factor receptor in breast tumours:
Evaluation in 282 cases. Intl. J. Cancer, 45, 255-262.
GULLICK WJ. (1991). Prevalence of aberrant expression of the
epidermal growth factor receptor in human cancers. Br. Med.
Bull., 47, 87-98.
GUSTERSON B, COWLEY G, SMITH JA AND OZANNE B. (1984).
Cellular localisation of human epidermal growth factor receptor.
Cell Biol. Int. Rep., 8, 649-658.
HIGASHIYAMA S, ABRAHAM JA, MILLER J, FIDDES JC AND
KLAGSBRUN M. (1991). A heparin-binding growth factor secret-
ed by macrophage-like cells that is related to EGF. Science, 251,
936-939.
HOCK RA, NEX0 E AND HOLLENBERG MD. (1980). Solubilization
and isolation of the human placenta receptor for epidermal
growth factor-urogastrone. J. Biol. Chem., 255, 10737-10743.
HOLLENBERG MD. (1990). Receptor solubilization, characterization,
and isolation. In Methods in Neurotransmitter Receptor Analjsis,
Yamamura, HI (ed.) pp. 111-145. Raven Press: New York.
HUANG S, TRUJILLO JM AND CHAKRABARTY S. (1992). Prolifera-
tion of human colon cancer cells: Role of epidermal growth
factor and transforming growth factora. Intl. J. Cancer, 52,
978-986.
HURTT MR, MOOSSY J, DONOVAN-PELUSO M AND LOCKER J.
(1992). Amplification of epidermal growth factor receptor gene in
gliomas: Histopathology and prognosis. J. Neuropathol. Exp.
Neurol., 51, 84-90.
IRISH JC AND BERNSTEIN A. (1993). Oncogenes in head and neck
cancer. LarYngoscope, 103, 42-52.
ISHITOYA J, TORIYAMA M, OGUCHI N, KITAMURA K, OHSHIMA
M, ASANO K AND YAMAMOTO T. (1989). Gene amplification
and overexpression of EGF receptor in squamous cell carcinomas
of the head and neck. Br. J. Cancer, 59, 559-562.
JORGENSEN PE, POULSEN SS AND NEXO E. (1988). Distribution of
i.v. administered epidermal growth factor in the rat. Reg. Pep-
tides, 23, 161-169.
KAWAMOTO T, TAKAHASHI K, NISHI M, KIMURA T, MATSUM-
URA T AND TANIGUCHI S. (1991). Quantitative assay of epider-
mal growth factor receptor in human squamous cell carcinomas
of the oral region by an avidin-biotin method. Jpn. J. Cancer
Res., 82, 403-410.
KEARSLEY JH, LENOARD JH, WALSH MD AND WRIGHT GR.
(1991). A comparison of epidermal growth factor receptor
(EGFR) and c-erbB-2 oncogene expression in head and neck
squamous cell carcinomas. Pathology, 23, 189-194.
KISSANE JM. (1990). Andersons Pathology, vol. 1, pp. 602, CV
Mosby: St Louis.
KRAUS MH, ISSING W, MIKI T, POPESCU NC AND AARONSON SA.
(1989). Isolation and characterization of ERBB3, a third member
of the ERBB/epidermal growth factor receptor family: Evidence
for overexpression in a subset of human mammary tumors. Proc.
Natl Acad. Sci. USA, 86, 9193-9197.ELISA of EGFR protein in head and neck carcinomas
ME Christensen et al
1493
KRUPP MN, CONNOLLY DT AND LANE MD. (1982). Synthesis,
turnover and down regulation of epidermal growth factor recep-
tors in human A431 epidermoid carcinoma cells and skin fibro-
blasts. J. Biol. Chem., 257, 11489-11496.
LEONARD JH, KEARSLEY JH, CHENEVIX-TRENCH G AND HAY-
WARD NK. (1991). Analysis of gene amplification in head-and-
neck squamous-cell carcinomas. Intl J. Cancer, 48, 511 -515.
MANGILI R, KEMENY DM, LI LK AND VIBERTY GC. (1987).
Development of a sensitive enzyme-linked immunosorbent assay
(ELISA) for quantitation of human IgG subclasses. J. All. Clin.
Immun., 79, 223.
MASSAGUE J AND PANDIELLA A. (1993). Membrane-anchored
growth factors. Annu. Rev. Biochem., 62, 515- 541.
MERRIT WD, WEISSLER MC, TURK BF AND GILMER TM. (1990).
Oncogene amplification in squamous cell carcinoma of the head
and neck. Arch. Otolarvngol. Head Neck Surg., 116, 1394- 1398.
NANNEY LB, MCKANNA JA, STOSCHECK CM. CARPENTER G &
KING LE. (1984). Visualization of epidermal growth factor recep-
tors in human epidermis. J. Invest. Dermatol., 82, 165-169.
NEAL DE. SHARPLES L. SMITH K, FENNELLY J, HALL RR, HARRIS
AL. (1990). The epidermal growth factor receptor and the prog-
nosis of bladder cancer. Cancer, 65, 1619- 1625.
NEX0 E AND HANSEN HF. (1985). Binding of epidermal growth
factor from man, rat and mouse to the human epidermal growth
factor receptor. Biochem. Biophys. Acta, 843, 101 -106.
NEX0 E, HOCK RA AND HOLLENBERG MD. (1979). Lectin-agarose
immobilization, a new method for detecting soluble membrane
receptors. J. Biol. Chem., 254, 8740-8743.
NICHOLSON S, SAINSBURY JRC, NEEDHAM GK, CHAMBERS P,
FARNDON JR AND HARRIS AL. (1988). Quantitative assays of
epidermal growth factor receptor in human breast cancer: Cut-off
points of clinical relevance. Intl. J. Cancer, 42, 36-41.
OZANNE B, SHUM A, RICHARDS CS, CASSELLS D. GROSSMAN D,
TRENT J, GUSTERSON B AND HENDLER F. (1986). Evidence for
an increase of EGF receptors in epidermoid malignancies. Cancer
Cells, 3, 41-49.
OZAWA S, UEDA M, ANDO N, SHIMIZU N AND ABE 0. (1989).
Prognostic significance of epidermal growth factor receptor in
esophageal squamous cell carcinomas. Cancer, 63, 2169-2173.
PLOWMAN GD, CULOUSCOU JM, WHITNEY GS, GREEN JM, CARL-
TON GW, FOY L, NEUBAUER MG AND SHOYAB M. (1993).
Ligand-specific activation of HER4/pl80"rb4, a fourth member of
the epidermal growth factor receptor family. Proc. Natl Acad.
Sci., 90, 1746-1760.
REINSCH CH. (1967). Smoothing by spline functions. Numer. Math.,
10, 177-183.
RIEDEL H, MASSOGLIA S, SCHLESSINGER J AND ULLBRICH A.
(1988). Ligand activation of overexpressed epidermal growth fac-
tor receptors transforms NIH 3T3 mouse fibroblasts. Proc. Natl
Acad. Sci. USA, 85, 1477-1481.
SANTINI J, FORMENTO J, FRANCOUAL M, MILANO G, SCHNEIDER
M, DASSONVILLE 0 AND DEMARD F. (1991). Characterization,
quantification and potential clinical value of the epidermal
growth factor receptor in head and neck squamous cell car-
cinomas. Head and Neck, 13, 132-139.
SATO JD, KAWAMOTO T, LE AD, MENDELSOHN J, POLIKOFF J
AND SATO GH. (1983). Biological effects in vitro of monoclonal
antibodies to human epidermal growth factor receptors. Mol.
Biol. Med., 1, 511 -529.
SASADA R, ONO Y. TANIYAMA Y, SHING Y, FOLKMAN J AND
IGARASHI K. (1993). Cloning and expression of cDNA encoding
human betacellulin, a new member of the EGF family. Biochem.
BiophYs. Res. Commun., 190, 1173- 1179.
SCAMBIA G, PANICI PB, BATTAGLIA F, FERRANDINA G, ALMA-
DORI G, PALUDETTI G, MAURIZI M AND MANCUSO S. (1991).
Receptors for epidermal growth factor and steroid hormones in
primary laryngeal tumors. Cancer, 67, 1347-1351.
SCHECHTER AL, HUNG M, VAIDYANATHAN L, WEINBERG RA,
YANGFENG TL, FRANCKE U, ULLRICH A. & COUSSENS L.
(1985). The neu gene: An erbB-homologous gene distinct from
and unlinked to the gene encoding the EGF receptor. Science,
229, 976-978.
SHOYAB M. PLOWMAN GD, MCDONALD VL. BRADLEY JG AND
TODARO GJ. (1989). Structure and function of human amphi-
regulin: A member of the epidermal growth factor family.
Science, 243, 1074-1076.
SLAUGHTER DP, SOUTHWICK HW AND SMEJKAL W. (1953). Field
cancerization' in oral stratified squamous epithelium: Clinical
implications of multicentric origin. Cancer, 6, 963 968.
SPIESSL B, BEAHRS OH, HERMANEK P, HUTTER RVP, SCHEIBE 0.
SOBIN LH AND WAGNER G. (1990). TNM Atlas Illustrated Guide
to the TNM/TNM Classification of Malignant Tumours, 3rd edn.
Springer: Berlin.
SPYRATOS F, MARTIN PM, HACENE K, ANDRIEU C, ROMAIN S,
FLOIRAS JL AND MAGDELENAT H. (1994). Prognostic value of
a solubilized fraction of EGF receptors in a primary breast
cancer using an immunoenzymatic assay a retrospective study.
Breast Cancer Res. Treat., 29, 85-95.
STAMPFER MR, PAN CH, HOSODA J, BARTHOLOMEW J, MENDEL-
SOHN J AND YASWEN P. (1993). Blockage of EGF receptor
signal transduction causes reversible arrest of normal and immor-
tal human mammary epithelial cells with synchronous reentry
into the cell cycle. E.p. Cell Res., 208, 175--188.
STROOBANT P, RICE AP, GULLICK WJ, CHENG DJ, KERR IM AND
WATERFIELD MD. (1985). Purification and characterization of
vaccinia virus growth factor. Cell, 42, 383-393.
VAN BERGEN EN HENEGOUWEN PMP, DEN HARTIGH JC. ROMEYN
P, VERKLEIJ AJ AND BOONSTRA J. (1992). The epidermal
growth factor receptor is associated with actin filaments. E.xp.
Cell Res., 199, 90-97.
VAN DAM PA, LOWE DG, WATSON JV, JAMES M, CHARD T, HUD-
SON CN AND SHEPHERD JH. (1991). Multiparameter flow-
cytometric quantitation of epidermal growth factor receptor and
c-erbB-2 oncoprotein in normal and neoplastic tissues of the
female genital tract. Gyneocol. Oncol., 42, 256-264.
WATERFIELD MD, MAYES ELV, STROOBANT P, BENNET PLP,
YOUNG S. GOODFELLOW PN, BANTING GS AND OZANNE B.
(1982). A monoclonal antibody to the epidermal growth factor
receptor. J. Cell Biochem., 20, 149- 161.
WRANN MM AND FOX CF. (1979). Identification of epidermal
growth factor receptors in a hyperproducing human epidermoid
carcinoma cell line. J. Biol. Chem., 254, 8083-8086.
YASUI W, SUMIYOSHI H. HATA J, KAMEDA T, OCHIAI A, ITO H
AND TAHARA E. (1988). Expression of epidermal growth factor
receptor in human gastric and colonic carcinomas. Cancer Res.,
48, 137-141.